DrugPatentWatch Database Preview

IDHIFA Drug Profile

« Back to Dashboard

When do Idhifa patents expire, and when can generic versions of Idhifa launch?

Idhifa is a drug marketed by Celgene Corp and is included in one NDA. There are four patents protecting this drug.

This drug has forty-seven patent family members in twenty-one countries.

The generic ingredient in IDHIFA is enasidenib mesylate. One supplier is listed for this compound. Additional details are available on the enasidenib mesylate profile page.

Summary for IDHIFA

International Patents:	47
US Patents:	4
Applicants:	1
NDAs:	1
Suppliers / Packagers:	1
Bulk Api Vendors:	33
Clinical Trials:	1
Patent Applications:	15
Drug Prices:	Drug price information for IDHIFA
DailyMed Link:	IDHIFA at DailyMed

Generic Entry Opportunity Date for IDHIFA

NDA:

209606

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for IDHIFA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Celgene Corp	IDHIFA	enasidenib mesylate	TABLET;ORAL	209606-001	Aug 1, 2017		RX	Yes	No			Y	Y
Celgene Corp	IDHIFA	enasidenib mesylate	TABLET;ORAL	209606-002	Aug 1, 2017		RX	Yes	Yes			Y	Y
Celgene Corp	IDHIFA	enasidenib mesylate	TABLET;ORAL	209606-001	Aug 1, 2017		RX	Yes	No				Y
Celgene Corp	IDHIFA	enasidenib mesylate	TABLET;ORAL	209606-002	Aug 1, 2017		RX	Yes	Yes

International Patents for IDHIFA

Country	Document Number	Estimated Expiration
Peru	08402016
World Intellectual Property Organization (WIPO)	2013102431
Israel	233503
New Zealand	627096